I’ve tried to go to some lengths in the past to emphasize the risks that come with an investment in Aptose Biosciences (APTO)
– a small biotech that has only recently seen its two lead compounds go
into the clinic. Not only is there the ever-present risk of clinical
trial failure (the large majority of Phase I cancer compounds fail) and
the meaningful risk of further dilutive financing, but there’s a
less-appreciated risk of investor sentiment (boredom, really), as
biotechs can drift lower without positive data to keep investors
engaged.
I continue to believe that, even with the
risks involved, Aptose is a very interesting early-stage speculation.
CG-806 could emerge as a hard-to-beat therapy option across a range of
hematological cancers, while APTO-253 may prove to be the first
effective drug targeting the “undruggable” MYC target, with potential
applications outside of hematology.
Read more here:
Aptose Drifting Ahead Of Real Data From Its Intriguing Clinical Assets
No comments:
Post a Comment